Core Viewpoint - Deyuan Pharmaceutical's Q4 2025 profit exceeded expectations due to adjustments in new drug R&D priorities and effective cost reduction measures, but profit forecasts for 2026 and 2027 have been lowered due to potential price pressure from centralized procurement of the core product "Furuitong" [1] Group 1: Financial Performance - In 2025, Deyuan Pharmaceutical reported a revenue of 1.058 billion yuan, representing a year-on-year increase of 21.80%, and a net profit attributable to shareholders of 237 million yuan, up 33.87%, driven by sales growth of products like "Furuitong" and "Bokaiqing" [3] - The revised profit forecasts for 2026 and 2027 are 174 million yuan and 140 million yuan, respectively, down from previous estimates of 218 million yuan and 200 million yuan [1] Group 2: Stock Performance - Over the past five trading days (February 9 to 13, 2026), Deyuan Pharmaceutical's stock price has decreased by 0.96%, with a price of 35.19 yuan at the close on February 13, reflecting a single-day drop of 0.54% [2] - The financing balance has declined for eight consecutive days, with a reduction of 10 million yuan over the last five days, indicating a 12.12% decrease and rising risk aversion among leveraged funds [2] Group 3: Recent Events - On February 5, the company released its 2025 performance report, which became a focal point of market attention following a detailed analysis by Shenwan Securities on February 9 regarding the Q4 performance [3] - The innovative drug pipeline includes DYX116 (a tri-target GLP-1 peptide), which has completed Phase I clinical trials for diabetes indications and received IND approval for weight loss indications, with Phase II trials expected to start in the first half of 2026 [1]
德源药业Q4利润超预期，但核心品种集采风险引盈利预测下调